|
1
|
Filipovich A, McClain K and Grom A:
Histiocytic disorders: Recent insights into pathophysiology and
practical guidelines. Biol Blood Marrow Transplant. 16 (1
Suppl):S82–S89. 2010. View Article : Google Scholar
|
|
2
|
Hayden A, Park S, Giustini D, Lee AY and
Chen LY: Hemophagocytic syndromes (HPSs) including hemophagocytic
lymphohistiocytosis (HLH) in adults: A systematic scoping review.
Blood Rev. 30:411–420. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takeuchi O and Akira S: Pattern
recognition receptors and inflammation. Cell. 140:805–820. 2010.
View Article : Google Scholar
|
|
4
|
Pachlopnik Schmid J, Côte M, Ménager MM,
Burgess A, Nehme N, Ménasché G, Fischer A and de Saint Basile G:
Inherited defects in lymphocyte cytotoxic activity. Immunol Rev.
235:10–23. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Risma K and Jordan MB: Hemophagocytic
lymphohistiocytosis: Updates and evolving concepts. Curr Opin
Pediatr. 24:9–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bichon A, Bourenne J, Allardet-Servent J,
Papazian L, Hraiech S, Guervilly C, Pauly V, Kaplanski G, Mokart D,
Gainnier M and Carvelli J: High mortality of HLH in ICU regardless
etiology or treatment. Front Med (Lausanne). 8:7357962021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Esteban YM, de Jong JLO and Tesher MS: An
overview of hemophagocytic lymphohistiocytosis. Pediatr Ann.
46:e309–e313. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Madkaikar M, Shabrish S and Desai M:
Current updates on classification, diagnosis and treatment of
hemophagocytic lymphohistiocytosis (HLH). Indian J Pediatr.
83:434–443. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spessott WA, Sanmillan ML, McCormick ME,
Patel N, Villanueva J, Zhang K, Nichols KE and Giraudo CG:
Hemophagocytic lymphohistiocytosis caused by dominant-negative
mutations in STXBP2 that inhibit SNARE-mediated membrane fusion.
Blood. 125:1566–1577. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jordan MB, Allen CE, Weitzman S,
Filipovich AH and McClain KL: How I treat hemophagocytic
lymphohistiocytosis. Blood. 118:4041–4052. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ramos-Casals M, Brito-Zerón P,
López-Guillermo A, Khamashta MA and Bosch X: Adult haemophagocytic
syndrome. Lancet. 383:1503–1516. 2014. View Article : Google Scholar
|
|
12
|
Shabbir M, Lucas J, Lazarchick J and
Shirai K: Secondary hemophagocytic syndrome in adults: A case
series of 18 patients in a single institution and a review of
literature. Hematol Oncol. 29:100–106. 2011. View Article : Google Scholar
|
|
13
|
Rivière S, Galicier L, Coppo P, Marzac C,
Aumont C, Lambotte O and Fardet L: Reactive hemophagocytic syndrome
in adults: A retrospective analysis of 162 patients. Am J Med.
127:1118–1125. 2014. View Article : Google Scholar
|
|
14
|
Tamamyan GN, Kantarjian HM, Ning J, Jain
P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F,
et al: Malignancy-associated hemophagocytic lymphohistiocytosis in
adults: Relation to hemophagocytosis, characteristics, and
outcomes. Cancer. 122:2857–2866. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gu Y, Shore RE, Arslan AA, Koenig KL, Liu
M, Ibrahim S, Lokshin AE and Zeleniuch-Jacquotte A: Circulating
cytokines and risk of B-cell non-Hodgkin lymphoma: A prospective
study. Cancer Causes Control. 21:1323–1333. 2010. View Article : Google Scholar
|
|
16
|
Vanmaris RMM and Rijkers GT: Biological
role of the soluble interleukin-2 receptor in sarcoidosis.
Sarcoidosis Vasc Diffuse Lung Dis. 34:122–129. 2017.PubMed/NCBI
|
|
17
|
Chang TY, Jaffray J, Woda B, Newburger PE
and Usmani GN: Hemophagocytic lymphohistiocytosis with MUNC13-4
gene mutation or reduced natural killer cell function prior to
onset of childhood leukemia. Pediatr Blood Cancer. 56:856–858.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Karlsson T: Secondary haemophagocytic
lymphohistiocytosis: Experience from the Uppsala university
hospital. Ups J Med Sci. 120:257–262. 2015. View Article : Google Scholar
|
|
19
|
Henter JI, Horne A, Aricó M, Egeler RM,
Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski
J and Janka G: HLH-2004: Diagnostic and therapeutic guidelines for
hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer.
48:124–131. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fardet L, Galicier L, Lambotte O, Marzac
C, Aumont C, Chahwan D, Coppo P and Hejblum G: Development and
validation of the HScore, a score for the diagnosis of reactive
hemophagocytic syndrome. Arthritis Rheumatol. 66:2613–2620. 2014.
View Article : Google Scholar
|
|
21
|
Debaugnies F, Mahadeb B, Nagant C,
Meuleman N, De Bels D, Wolff F, Gottignies P, Salaroli A, Borde P,
Voué M and Corazza F: Biomarkers for early diagnosis of
hemophagocytic lymphohistiocytosis in critically Ill patients. J
Clin Immunol. 41:658–665. 2021. View Article : Google Scholar
|
|
22
|
Hu S, Bansal P, Lynch D, Rojas Hernandez
CM and Dayao Z: Rituximab, etoposide, methylprednisolone, high-dose
cytarabine, and cisplatin in the treatment of secondary
hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma:
A case report and review of the literature. J Med Case Rep.
10:3652016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dunleavy K, Pittaluga S, Maeda LS, Advani
R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, et
al: Dose-adjusted EPOCH-rituximab therapy in primary mediastinal
B-cell lymphoma. N Engl J Med. 368:1408–1416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chellapandian D, Das R, Zelley K, Wiener
SJ, Zhao H, Teachey DT and Nichols KE; EBV-HLH Rituximab Study
Group, : Treatment of Epstein Barr virus-induced haemophagocytic
lymphohistiocytosis with rituximab-containing
chemo-immunotherapeutic regimens. Br J Haematol. 162:376–382. 2013.
View Article : Google Scholar
|
|
25
|
University of Michigan Rogel Cancer
Center, . A pilot study of ruxolitinib in secondary hemophagocytic
syndrome. https://clinicaltrials.gov/ct2/show/NCT02400463?cond=NCT02400463&draw=2&rank=1January
28–2022
|
|
26
|
Children's Hospital of Philadelphia, .
Tocilizumab and hemophagocytic lymphohistiocytosis (HLH).
https://clinicaltrials.gov/ct2/show/NCT02007239?cond=NCT02007239&draw=2&rank=1January
28–2022
|
|
27
|
M.D. Anderson Cancer Center, . Alemtuzumab
or tocilizumab in combination with etoposide and dexamethasone for
the treatment of adult patients with hemophagocytic
lymphohistiocytosis. https://clinicaltrials.gov/ct2/show/NCT02385110?cond=NCT02385110&draw=2&rank=1January
28–2022
|
